
Regeneron Pharmaceuticals guidance
$959.12+0.71%Close 17 Nov 2026 · Market value $102.6B
In its results release of 30 Oct 2026 (Q3 FY2026), Regeneron Pharmaceuticals gave 5 forecasts in figures, among them gross margin (gaap) of 80% for FY2026.
Read from the company's earnings releases and outlook updates of the last two years. Each forecast is shown with the sentence or table row it was read from; what a release does not state in figures is not shown.
Latest guidance given with Q3 FY2026 results, 30 Oct 2026
| Measure | Period | Guidance | As stated |
|---|
| Gross margin · GAAP | FY2026 | 80% | GAAP gross margin on net product sales 80% |
|---|
| Gross margin · Adjusted | FY2026 | 86% | Non-GAAP gross margin on net product sales 86% |
|---|
| Capital expenditures | FY2026 | $1.05B to $1.10B | Capital expenditures $1.050-$1.100 billion |
|---|
| Tax rate · GAAP | FY2026 | 14% | GAAP effective tax rate 14% |
|---|
| Tax rate · Adjusted | FY2026 | 15% | Non-GAAP effective tax rate 15% |
|---|
Source: the company's earnings release.
Guidance against results above 1 · within 1 · below 0
The last range given before each period closed, how it moved between releases, and the figure then filed. A measure the company defines itself, or one not comparable with the filed figure, has no verdict.
| Measure | Period | Last guidance | Revisions | Delivered | Result |
|---|
| Gross margin · GAAP | FY2026 | 80% | Raised twice, lowered once | — | To come |
|---|
| Gross margin · Adjusted | FY2026 | 86% | Raised twice | — | To come |
|---|
| Capital expenditures | FY2026 | $1.05B to $1.10B | Raised once, lowered twice | — | To come |
|---|
| Tax rate · GAAP | FY2026 | 14% | Raised twice | — | To come |
|---|
| Tax rate · Adjusted | FY2026 | 15% | Raised twice | — | To come |
|---|
| Capital expenditures | FY2025 | $850M to $890M | Raised once, lowered once | $898M | Above the range |
|---|
| Tax rate · GAAP | FY2025 | 14% | Raised once | 13.88% | Within the range |
|---|
REGN in the terminal
Guidance said on earnings calls, every revision charted, and guidance set against the analysts' consensus.